Compare ANNX & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANNX | OCSL |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 1.1B |
| IPO Year | 2020 | 2007 |
| Metric | ANNX | OCSL |
|---|---|---|
| Price | $5.45 | $11.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | ★ $16.50 | $12.63 |
| AVG Volume (30 Days) | ★ 2.1M | 725.0K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 12.73% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16,320.74 | $0.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.85 | $10.63 |
| 52 Week High | $7.18 | $14.77 |
| Indicator | ANNX | OCSL |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 48.08 |
| Support Level | $4.80 | $11.94 |
| Resistance Level | $5.61 | $13.89 |
| Average True Range (ATR) | 0.28 | 0.24 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 55.96 | 56.98 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.